Eribulin in Recurrent/Metastatic Breast Cancer (MBC)
Indian Journal of Gynecologic Oncology, ISSN: 2363-8400, Vol: 17, Issue: 3
2019
- 1Citations
- 7Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
Introduction: There is no standard chemotherapy for patients with MBC who progress after exposure to anthracycline and taxane. We conducted this study to assess the outcome of patients who were treated with eribulin. Methods: This was a retrospective study of patients with MBC who were treated with eribulin from December 2016 to March 2018 in Cancer Institute, Chennai. Results: Twelve patients with MBC previously exposed to both anthracycline and taxane, who received eribulin, were included in this analysis. The overall response rate was 33%. With a median follow-up of 26 months, the median PFS and median OS were 3.5 months and 13.5 months, respectively. Grade 3 neuropathy occurred in 16% of patients. Conclusion: Eribulin is an option in heavily pre-treated MBC considering the promising long-term outcome. Patients with pre-existing neuropathy should not be considered for eribulin.
Bibliographic Details
Springer Science and Business Media LLC
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know